TrialBlood neoplasia2025

Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study.

Mrinal M Patnaik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.